BRIEF-Sarepta Therapeutics says U.S. Commercial launch for Exondys 51 planned to commence immediately

* Sarepta therapeutics announces fda accelerated approval of

exondys 51(tm) (eteplirsen) injection, an exon skipping therapy

to treat duchenne muscular dystrophy (dmd) patients amenable to

skipping exon 51

Read more